DAFNA Capital Management’s Adaptimmune Therapeutics ADAP Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q4 | – | Sell |
-341,064
| Closed | -$324K | – | 83 |
|
|
2024
Q3 | $324K | Hold |
341,064
| – | – | 0.08% | 78 |
|
|
2024
Q2 | $333K | Hold |
341,064
| – | – | 0.08% | 76 |
|
|
2024
Q1 | $539K | Sell |
341,064
-10,000
| -3% | -$15.8K | 0.12% | 65 |
|
|
2023
Q4 | $278K | Hold |
351,064
| – | – | 0.07% | 67 |
|
|
2023
Q3 | $274K | Hold |
351,064
| – | – | 0.09% | 66 |
|
|
2023
Q2 | $325K | Hold |
351,064
| – | – | 0.09% | 66 |
|
|
2023
Q1 | $383K | Hold |
351,064
| – | – | 0.11% | 65 |
|
|
2022
Q4 | $513K | Hold |
351,064
| – | – | 0.14% | 62 |
|
|
2022
Q3 | $377K | Hold |
351,064
| – | – | 0.1% | 79 |
|
|
2022
Q2 | $597K | Hold |
351,064
| – | – | 0.16% | 71 |
|
|
2022
Q1 | $723K | Buy |
351,064
+214,798
| +158% | +$442K | 0.19% | 76 |
|
|
2021
Q4 | $511K | Buy |
+136,266
| New | +$511K | 0.13% | 80 |
|
|
2016
Q3 | – | Sell |
-24,955
| Closed | -$203K | – | 78 |
|
|
2016
Q2 | $203K | Sell |
24,955
-63,145
| -72% | -$514K | 0.16% | 79 |
|
|
2016
Q1 | $716K | Buy |
88,100
+40,000
| +83% | +$325K | 0.62% | 46 |
|
|
2015
Q4 | $580K | Buy |
+48,100
| New | +$580K | 0.52% | 49 |
|